标题
Novel drugs in clinical development for hepatocellular carcinoma
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 24, Issue 8, Pages 1075-1082
出版商
Informa Healthcare
发表日期
2015-06-25
DOI
10.1517/13543784.2015.1058776
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Resistance development after long-term sorafenib exposure in hepatocellular cancer cell lines and risk of rebound growth and epithelial to mesenchymal transition.
- (2017) Chris Verslype et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma (HCC).
- (2017) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- When Is Good Enough Really Good Enough? Defining the Role of Radiation in Low-Risk Ductal Carcinoma In Situ
- (2015) Benjamin D. Smith JOURNAL OF CLINICAL ONCOLOGY
- Appropriate Role for Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Patients With Early-Stage Breast Cancer
- (2015) Gary H. Lyman JOURNAL OF CLINICAL ONCOLOGY
- SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
- (2015) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- (2015) Martin Schlumberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- The clue of a possible etiology about spontaneous regression of hepatocellular carcinoma: a perspective on pathology
- (2015) Lian-Tang Wang et al. OncoTargets and Therapy
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2015) et al. JOURNAL OF HEPATOLOGY
- Allosteric MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular Carcinoma
- (2015) Roberta Schmieder et al. NEOPLASIA
- A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma
- (2014) H. Y. Lim et al. CLINICAL CANCER RESEARCH
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- (2014) Andrew X. Zhu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
- (2014) Bradley J Monk et al. LANCET ONCOLOGY
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Time to evolve trial design after everolimus failure
- (2014) Josep M. Llovet Nature Reviews Clinical Oncology
- Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study
- (2013) Jordi Bruix et al. EUROPEAN JOURNAL OF CANCER
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
- (2013) Josep M. Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
- (2013) Jeong Heo et al. NATURE MEDICINE
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regorafenib for cancer
- (2012) Dirk Strumberg et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma
- (2012) Shunsuke Kondo et al. International Journal of Clinical Oncology
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
- (2012) Armando Santoro et al. LANCET ONCOLOGY
- Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197
- (2011) Sudharshan Eathiraj et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy
- (2011) Jeong Heo et al. MOLECULAR THERAPY
- Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide
- (2011) Alan Melcher et al. MOLECULAR THERAPY
- ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity
- (2010) N. Munshi et al. MOLECULAR CANCER THERAPEUTICS
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer
- (2009) C. Iverson et al. CANCER RESEARCH
- Spontaneous regression of hepatocellular carcinoma: a systematic review
- (2009) Susana Oquiñena et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma
- (2008) Daniel H. Palmer et al. HEPATOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started